Summit Therapeutics plc Summit Therapeutics Plc : Result Of Agm

 
TIDMSUMM 
 
 
   Summit Therapeutics plc 
 
   ('Summit' or 'the Company') 
 
   RESULT OF ANNUAL GENERAL MEETING 
 
   Oxford, UK, 18 July 2017 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: 
SUMM), the drug discovery and development company advancing therapies 
for Duchenne muscular dystrophy and Clostridium difficile infection, 
announces that all resolutions proposed to shareholders at the Company's 
Annual General Meeting ('AGM') held earlier today were duly passed. The 
results of the proxy votes lodged in advance and at the meeting will be 
available shortly from the Investors section of Summit's website, 
www.summitplc.com. 
 
   About Summit Therapeutics 
 
   Summit is a biopharmaceutical company focused on the discovery, 
development and commercialisation of novel medicines for indications for 
which there are no existing or only inadequate therapies. Summit is 
conducting clinical programs focused on the genetic disease Duchenne 
muscular dystrophy and the infectious disease C. difficile infection. 
Further information is available at www.summitplc.com and Summit can be 
followed on Twitter (@summitplc). 
 
   For more information, please contact: 
 
 
 
 
Summit 
 Glyn Edwards / Richard Pye (UK office)         Tel: [phone] 
 Erik Ostrowski / Michelle Avery (US office)    [phone] 
Cairn Financial Advisers LLP 
 (Nominated Adviser)                            Tel: [phone] 
 Liam Murray / Tony Rawlinson 
N+1 Singer 
 (Broker)                                       Tel: [phone] 
 Aubrey Powell / Lauren Kettle 
MacDougall Biomedical Communications 
 (US media contact)                            Tel: [phone] 
 Karen Sharma                                  [e-mail] 
Consilium Strategic Communications            Tel: [phone] 
 (Financial public relations, UK)              [e-mail] 
 Mary-Jane Elliott / Sue Stuart / 
 Jessica Hodgson / Lindsey Neville 
 
 
 
 
   -END- 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Summit Therapeutics plc via Globenewswire 
 
 
  http://www.summitplc.com/ 
 

(END) Dow Jones Newswires

July 18, 2017 10:41 ET (14:41 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.